Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date.

ABSTRACT: The quest for the right combination of bronchodilators with different mechanisms of action such as long-acting muscarinic antagonists and long-acting β-agonists in the management of stable moderate-to-severe chronic obstructive pulmonary disease (COPD) is a topic of intense research activity currently, given the rising morbidity and mortality due to this disease. The fixed-dose combination of aclidinium bromide and formoterol fumarate in a single inhaler seems to offer superior advantages over either drugs given alone or as separate inhalers concurrently. Since the fixed-dose combination needs to be given twice daily, it is likely to achieve control of symptoms most crucial to the quality of life in COPD, namely, the morning hours. This is reflected in significant trough FEV1 (forced expir

SUBMITTER: Moitra S 

PROVIDER: S-EPMC4396584 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature